Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy

NCT04762069 is registered in ClinicalTrials.gov with CNS Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04762069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04762069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Lead sponsor
CNS Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 18, 2021
Completion date
July 15, 2026
Enrollment
252 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme, adult